Evidence map›Paper›PMID 40811154›Full record

ArticlePloS one2025

Risk stratification for the prediction of skeletal-related events in patients with castration-resistant prostate cancer with bone metastases.

Masanori Hamada, Eiji Nakata, Ryuichi Nakahara, Shinsuke Sugihara, Haruyoshi Katayama, Takuto Itano, Tomohiro Inoue, Shota Takihira, Yoshiteru Akezaki, Toshifumi Ozaki

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masanori HamadaDivision of Physical Medicine and Rehabilitation, Okayama University Hospital, Okayama City, Okayama, Japan.ORCID https://orcid.org/0000-0001-7355-3229
Eiji NakataDepartment of Orthopedic Surgery, Okayama University Hospital, Okayama City, Okayama, Japan.ORCID https://orcid.org/0000-0002-5971-4142
Ryuichi NakaharaDepartment of Orthopedic Surgery, Okayama University Hospital, Okayama City, Okayama, Japan.
Shinsuke SugiharaDepartment of Orthopedic Surgery, Shikoku Cancer Center, Matsuyama City, Ehime, Japan.
Haruyoshi KatayamaDepartment of Orthopedic Surgery, Okayama University Hospital, Okayama City, Okayama, Japan.
Takuto ItanoDepartment of Orthopedic Surgery, Okayama University Hospital, Okayama City, Okayama, Japan.
Tomohiro InoueDepartment of Orthopedic Surgery, Okayama University Hospital, Okayama City, Okayama, Japan.
Shota TakihiraDepartment of Orthopedic Surgery, Okayama University Hospital, Okayama City, Okayama, Japan.
Yoshiteru AkezakiDivision of Physical Therapy, Kochi Professional University of Rehabilitation, Tosa, Kochi, Japan.
Toshifumi OzakiDepartment of Orthopedic Surgery, Okayama University Hospital, Okayama City, Okayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skeletal-related events (SREs) are common in patients with bone metastases from castration-resistant prostate cancer (CRPC). Despite advances in prostate cancer treatment, clinically validated predictive models for SREs in CRPC patients with bone metastases remain elusive. This gap in prognostic tools hinders optimal patient management and treatment planning for this high-risk population. This study aimed to develop a prediction model for SRE by investigating potential risk factors and classifying them into different groups. This model can be used to identify patients at high risk of SREs who need close follow-up. Between 2004 and 2013, 68 male patients with bone metastases from CRPC who were treated at our institute were evaluated for survival without SREs and survival without SREs of the spinal cord. The study analyzed clinical data at enrollment to identify risk factors for initial and spinal SREs. Multivariate analysis revealed that a high count of metastatic vertebrae, along with visceral or lymph node metastases, were significant risk factors. Patients were categorized into four subgroups based on the number of vertebral metastases and presence of visceral or lymph node metastases: 1) extensive vertebral and both types of metastases, 2) extensive vertebral without additional metastases, 3) some vertebral with other metastases, 4) some vertebral without additional metastases. The first SRE and spinal SRE occurred significantly sooner in the first subgroup compared to others. Incidence rates at 12 months for the first SRE were 56%, 40%, 27%, and 5%, and for the first spinal SRE were 47%, 40%, 27%, and 0% respectively. Patients with extensive vertebral and additional metastases require vigilant monitoring to mitigate SREs.

Indexed as

Bone NeoplasmsProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overHumansMaleMiddle AgedPrognosisRisk AssessmentRisk Factors

Identifiers

PMID40811154
PMCPMC12352678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.